L

Landmark Bio

Cell and gene therapy CDMO services

Production Operator

Full-TimePosted on 10/20/2026
No salary listed
Entry
Bilbao, Biscay, Spain
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • Technical education in laboratory operations, biotechnology, pharmaceutical manufacturing, chemical processes, or a related field.
  • English proficiency sufficient to understand and follow technical documentation and communicate in a manufacturing environment.
Responsibilities
  • Perform DNA, RNA, and lipid nanoparticle manufacturing operations under supervision, including enzymatic reactions, purification, filtration, formulation, and product conditioning.
  • Prepare buffers, solutions, reagents, and materials required for manufacturing activities.
  • Operate production and analytical equipment, including chromatography and tangential flow filtration systems, biosafety cabinets, electrophoresis equipment, and spectrophotometers.
  • Prepare, assemble, and operate process equipment and systems.
  • Work in controlled environments and apply appropriate contamination-control measures to prevent product contamination and degradation.
  • Clean, prepare, and perform basic maintenance of production equipment and areas.
  • Follow approved standard operating procedures, batch records, and work instructions in accordance with Good Manufacturing Practice requirements.
  • Record manufacturing activities in accordance with Good Documentation Practices and data-integrity requirements.
  • Identify and promptly report process deviations, equipment issues, or unexpected analytical results.
Desired Qualifications
  • Previous experience in a production, laboratory, or biotechnology environment.
  • Experience with RNA, DNA, lipid nanoparticles, molecular biology techniques, chromatography, filtration, formulation, or bioprocess equipment.
  • Knowledge of Good Manufacturing Practice and Good Documentation Practices.

About the company

Landmark Bio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. It provides end-to-end services including drug development consulting, process analytical development, cGMP manufacturing, and CMC regulatory consulting to turn research into clinical programs. Its offerings are tailored services rather than products, delivered through collaborations with academia, physicians, biopharma, and research hospitals to address manufacturing costs and complexities. Its goal is to help programs reach clinical trials and commercial use faster while meeting regulatory standards and budget constraints, increasing patient access to advanced therapies.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Watertown, Massachusetts

Founded

N/A

Get referred to Landmark Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded up to $18.3 million in April 2026 for TRANSFORM-EV.
  • Mass General Brigham collaboration can funnel recurring early-stage projects into Watertown.
  • ChromaTan and Landmark Bio won NIIMBL support for scalable AAV manufacturing platform development.

What critics are saying

  • Artis BioSolutions controls Landmark Bio, so a parent funding pullback hits operations immediately.
  • ARPA-H TRANSFORM-EV lasts three years; failed milestones would weaken Landmark Bio’s follow-on credibility.
  • Cell-therapy CDMO demand stays lumpy; losing Galapagos or InnDura programs would cut utilization fast.

What makes Landmark Bio unique

  • Landmark Bio’s 44,000-square-foot Watertown facility offers end-to-end CGT development and GMP manufacturing.
  • Artis BioSolutions acquired Landmark Bio in April 2025, adding broader genetic-medicine scale.
  • Mass General Brigham partnered with Landmark Bio in October 2025 for translational cell and gene therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget
  • Conference Attendance Budget
  • Wellness Program
  • Mental Health Support
  • Stock Options
  • Company Equity
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Connect Iredell
Apr 16th, 2026
Landmark Bio secures up to $18.3M ARPA-H funding for EV manufacturing platform

Landmark Bio has secured up to $18.3 million in funding from ARPA-H through its TRANSFORM-EV programme, with support from national advisory firm EverGlade. The three-year award will fund development of a continuous manufacturing platform for extracellular vesicles, potentially benefiting advanced therapies including viral vectors and cell therapies. The project aims to overcome current low-yield, high-cost batch manufacturing methods by integrating advanced upstream, downstream and analytical technologies. EverGlade supported Landmark Bio through negotiations, including multiple redesigns of work statements, milestones and financial documentation. EverGlade specialises in helping innovators navigate federal funding from agencies including ARPA-H, BARDA and DARPA. Landmark Bio, an Artis BioSolutions company, operates from Watertown, Massachusetts, providing process development and GMP manufacturing for advanced therapies.

Business Wire
Feb 17th, 2026
Artis BioSolutions names Dr Kate Broderick chief scientific innovation officer to advance synthetic DNA strategy

Artis BioSolutions has appointed Dr Kate Broderick as Chief Scientific Innovation Officer, effective 9 February 2026. She will lead scientific strategy and innovation initiatives across the company's platform for developing and manufacturing genetic medicines. Dr Broderick brings over 25 years of experience in nucleic acid medicine and DNA- and RNA-based vaccine development. Most recently, she served as Chief Innovation Officer at Maravai LifeSciences. Previously, at Inovio Pharmaceuticals, she led R&D teams that advanced multiple clinical-stage programmes, including a DNA-based COVID-19 vaccine through Phase 3 testing, and secured over $100 million in non-dilutive funding. The appointment comes as Artis prepares to close its acquisition of Syngoi Technologies, expected in the first quarter of 2026. Dr Broderick holds a PhD in Molecular Genetics from the University of Glasgow.

Business Wire
Apr 3rd, 2025
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio

Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its...